Establishing nomograms for predicting disease-free survival and overall survival in patients with breast cancer

Figures & data

Figure 1. Based on the study flowchart, 138 were included in this retrospective analysis. The patients were divided into a recurrence group and non-recurrence group based on the recurrence after treatment. IDBC: invasive ductal breast cancer.

Table 1. Univariate and multivariate regression analysis results for recurrence.

Variables	Recurrence group (n = 32)	Non-recurrence group (n = 106)	Univariate Cox analysis		Multivariate Cox analysis
			HR[95%CI]	p value	HR[95%ci]	p value
Age	55.41 ± 12.69	55.90 ± 11.65	1.00[0.97,1.03]	0.910
ALDH1	14(43.75%)	14(13.21%)	4.79[2.33,9.85]	<0.001	4.36[2.07,9.21]	<0.001
p-AKT	20(62.50%)	34(32.08%)	3.20[1.56,6.57]	0.002	2.80[1.35,5.84]	0.006
Size	19(59.38%)	45(42.45%)	1.71[0.85,3.46]	0.136
LN (+)	23(71.88%)	41(38.68%)	3.51[1.62,7.60]	0.001
Pathological stage
I	5(15.62%)	40(37.74%)
II	12(37.50%)	51(48.11%)	1.74[0.61,4.93]	0.300	1.83[0.64,5.23]	0.260
III	15(46.88%)	15(14.15%)	5.74[2.08,15.80]	0.001	6.42[2.31,17.81]	<0.001
ER, PR, HER2 negative	11(34.38%)	26(24.53%)	1.50[0.75,3.21]	0.240

ALDH1: aldehyde dehydrogenase 1; LN: lymph node; ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; HR: hazard ratio; CI: confidence interval.

Figure 2. Prediction nomogram for the 3-yr and 5-yr DFS using ALDH1, p-AKT, and pathological stages in BC patients (A). Calibration curve and ROC curve of the nomogram for predicting DFS in BC patients (B). (a, b) The consistence of predicted 3-yr and 5-yr DFS and the actual 3-yr and 5-yr DFS. (c) The AUC calibration plot. Kaplan-Meier curves for the DFS of BC patients after PI-based stratification (C). DFS: disease-free survival; ALDH1: aldehyde dehydrogenase 1; ROC: receiver operating characteristic; BC: breast cancer; AUC: area under the ROC curve.

Table 2. Univariate and multivariate regression analysis results for mortality.

Variables	Mortality group (n = 25)	Survival group (n = 113)	Univariate Cox analysis		Multivariate Cox analysis
			HR[95%CI]	p value	HR[95%CI]	p value
Age	54.64 ± 13.51	56.04 ± 11.50	0.99[0.96,1.03]	0.686
ALDH1	10 (40.00%)	18 (15.93%)	3.92[1.72,8.91]	0.001	2.89[1.25,6.68]	0.013
p-AKT	16 (64.00%)	38 (33.63%)	3.15[1.39,7.15]	0.006	2.99[1.29,6.95]	0.011
Size	15 (60.00%)	49 (43.36%)	1.70[0.77,3.79]	0.193
LN (+)	18 (72.00%)	46 (40.71%)	3.27[1.36,7.84]	0.008
Pathological stage
I	4 (16.00%)	41 (36.28%)
II	8 (32.00%)	55 (48.67%)	1.42[0.43,4.70]	0.571	1.85[0.53,6.38]	0.333
III	13 (52.00%)	17 (15.04%)	5.62[1.83,17.26]	0.003	6.38[2.06,19.79]	0.001
ER, PR, HER2 negative	11 (44.00%)	26 (23.01%)	2.33[1.06,5.14]	0.036	2.37[1.03,5.46]	0.042

ALDH1: aldehyde dehydrogenase 1; LN: lymph node; ER, oestrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor; HR: hazard ratio; CI: confidence interval.

Figure 3. Prediction nomogram for the 3-yr and 5-yr OS using ALDH1, p-AKT, pathological stages and ER^-/PR^-/HER2^- in BC patients (A). Calibration curve and ROC of the nomogram for OS in BC patients (B). (a, b) The consistence of predicted 3-yr and 5-yr OS and the actual 3-yr and 5-yr OS. (c) AUC calibration plot. Kaplan-Meier curves for the OS of BC patients after pi-based mortality stratification (C). OS: overall survival; ALDH1: aldehyde dehydrogenase 1; ROC: receiver operating characteristic; BC: breast cancer; AUC: area under the ROC curve; ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; PR: progesterone receptor.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.